ProPhase Labs (NASDAQ:PRPH) Stock Passes Above 200 Day Moving Average – Should You Sell?

ProPhase Labs, Inc. (NASDAQ:PRPH)’s share price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.36 and traded as high as $0.52. ProPhase Labs shares last traded at $0.43, with a volume of 5,585,007 shares.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised ProPhase Labs to a “hold” rating in a report on Saturday.

ProPhase Labs Stock Performance

The stock has a market capitalization of $18.01 million, a P/E ratio of -0.34 and a beta of -0.78. The company has a quick ratio of 0.93, a current ratio of 0.96 and a debt-to-equity ratio of 0.20. The business has a fifty day moving average price of $0.37 and a 200-day moving average price of $0.36.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $1.25 million for the quarter, compared to the consensus estimate of $3.55 million. On average, sell-side analysts expect that ProPhase Labs, Inc. will post -1.27 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PRPH. Sykon Capital LLC bought a new position in shares of ProPhase Labs during the second quarter valued at $252,000. Citizens Financial Group Inc. RI purchased a new stake in ProPhase Labs during the first quarter valued at $109,000. Josh Arnold Investment Consultant LLC purchased a new stake in ProPhase Labs during the first quarter valued at $100,000. XTX Topco Ltd purchased a new stake in ProPhase Labs during the second quarter valued at $40,000. Finally, Cerity Partners LLC purchased a new stake in ProPhase Labs during the first quarter valued at $38,000. 9.45% of the stock is owned by institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.